Toward the next generation of NK cell-based adoptive cancer immunotherapy.
about
An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.Cell transfer therapy for cancer: past, present, and future.Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma.Trial Watch: Lenalidomide-based immunochemotherapy.Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor.
P2860
Toward the next generation of NK cell-based adoptive cancer immunotherapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Toward the next generation of NK cell-based adoptive cancer immunotherapy.
@en
type
label
Toward the next generation of NK cell-based adoptive cancer immunotherapy.
@en
prefLabel
Toward the next generation of NK cell-based adoptive cancer immunotherapy.
@en
P2093
P2860
P356
P1433
P1476
Toward the next generation of NK cell-based adoptive cancer immunotherapy
@en
P2093
Adelheid Cerwenka
Matthias Miller
P2860
P304
P356
10.4161/ONCI.23811
P577
2013-04-01T00:00:00Z